CommercialFormer Inizio Evoke Executives Launch Flex Marketing

Former Inizio Evoke Executives Launch Flex Marketing

-

A group of former executives from health communications firm Inizio Evoke have launched Flex Marketing, a new independent agency catering to pharmaceutical, biotech, medtech, and health tech clients.
Flex Marketing, based in San Francisco, will provide services including market and customer research, strategic planning, market conditioning, brand development, and data-driven analytics. The agency aims to offer tailored marketing solutions with a focus on flexibility and adaptability.
The agency was founded by four industry professionals, each bringing extensive experience in health marketing. All four will hold the title of partner, with specific focus areas.

Gelling will lead client engagement. He previously worked at Giant Creative Strategy as president before its acquisition by Evoke in 2018. He later served as president of Evoke’s San Francisco office for five years.
Amber Rogers will oversee brand strategy. She previously spent nearly 15 years at Evoke, where she held the role of executive VP of brand strategy. Before that, she worked at Giant and led the West Coast office of Dorland Global Health, which was acquired by Huntsworth Health, later becoming part of Inizio.
Jason Luis will manage omnichannel strategy. He has previously led analytics teams at Doremus, FCB Global, and Evoke. During his time at Evoke from 2014 to 2024, he held roles such as executive VP of channel strategy and analytics and managing director of omnichannel.
Michelle Green will lead Flex’s creative department. She began her career as a copywriter at various agencies, including Kane and Finkel, where she worked for 13 years and became creative director. She later spent a decade at Inizio Evoke in creative director roles.
Flex Marketing will operate independently and serve clients globally.

Life Sciences Voice Logo mobile
+ posts

Latest news

Gilead Secures Arenavirus Vaccine Programs from Hookipa for $10 Million

Gilead Sciences has acquired exclusive ownership of two arenavirus-based immunotherapy programs for hepatitis B (HBV) and human immunodeficiency virus...

Sanofi Acquires Vigil Neuroscience for $470M to Boost Alzheimer’s Drug Pipeline

Sanofi is acquiring Vigil Neuroscience for $470 million to expand its Alzheimer’s drug portfolio, focusing on TREM2-targeting therapies like...

Moderna Delays Flu-COVID Combo Vaccine Filing Amid FDA Request

Moderna has announced that it is withdrawing its application for approval from the U.S. Food and Drug Administration (FDA)...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you